CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Compugen presents immuno-oncology pipeline update, targets COM701 interim analysis in Q1 2027

By Public Technologies
  • Compugen expects cash to fund operations into 2029, with a $117.5 million balance as of September 30, 2026.
  • An interim analysis of the COM701 MAIA-ovarian maintenance therapy trial is projected for the first quarter of 2027.
  • AstraZeneca's rilvegostomig program spans 12 Phase 3 trials, with ARTEMIDE-Biliary01 data anticipated in the second half of 2027.
  • Rilvegostomig could generate up to $195 million in additional milestone payments, with tiered royalties up to mid-single digits.
  • The GS-0321 licensing agreement with Gilead offers up to $758 million in additional milestones, with single-digit to low-double-digit tiered royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.